About Emergent BioSolutions (NYSE:EBS)
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200
Debt
Debt-to-Equity Ratio0.01%
Current Ratio4.85%
Quick Ratio3.42%
Price-To-Earnings
Trailing P/E Ratio28.69
Forward P/E Ratio23.40
P/E Growth1.06
Sales & Book Value
Annual Sales$560.87 million
Price / Sales4.81
Cash Flow$2.8118 per share
Price / Cash19.39
Book Value$18.47 per share
Price / Book2.95
Profitability
EPS (Most Recent Fiscal Year)$1.90
Net Income$82.59 million
Net Margins14.73%
Return on Equity13.66%
Return on Assets9.54%
Miscellaneous
Employees1,256
Outstanding Shares49,490,000
Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent BioSolutions' stock symbol?
Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent BioSolutions' stock buyback program work?
Emergent BioSolutions announced that its Board of Directors has initiated a stock repurchase plan on Friday, March 23rd 2018, which allows the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.
How were Emergent BioSolutions' earnings last quarter?
Emergent BioSolutions (NYSE:EBS) issued its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts' consensus estimates of $0.70 by $0.04. The biopharmaceutical company earned $193.80 million during the quarter, compared to analysts' expectations of $189.96 million. Emergent BioSolutions had a net margin of 14.73% and a return on equity of 13.66%. The business's quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.74 EPS. View Emergent BioSolutions' Earnings History.
When is Emergent BioSolutions' next earnings date?
What price target have analysts set for EBS?
4 Wall Street analysts have issued 12-month price objectives for Emergent BioSolutions' stock. Their predictions range from $43.00 to $60.00. On average, they anticipate Emergent BioSolutions' share price to reach $52.75 in the next year. View Analyst Ratings for Emergent BioSolutions.
Who are some of Emergent BioSolutions' key competitors?
Some companies that are related to Emergent BioSolutions include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM) and Taro Pharmaceutical Industries (TARO).
Who are Emergent BioSolutions' key executives?
Emergent BioSolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)
- Mr. Daniel J. Abdun-Nabi, Pres, CEO & Director (Age 63)
- Mr. Robert G. Kramer Sr., Exec. VP of Admin., CFO, Treasurer & Principal Accounting Officer (Age 61)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations and Pres of Biodefense Division (Age 47)
- Dr. W. James Jackson, Sr. VP & Chief Scientific Officer (Age 63)
Has Emergent BioSolutions been receiving favorable news coverage?
Headlines about EBS stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Emergent BioSolutions earned a media sentiment score of 0.05 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Emergent BioSolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent BioSolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $54.52.
How big of a company is Emergent BioSolutions?
Emergent BioSolutions has a market capitalization of $2.69 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent BioSolutions employs 1,256 workers across the globe.
How can I contact Emergent BioSolutions?
Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent BioSolutions (EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent BioSolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Emergent BioSolutions (NYSE:EBS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Emergent BioSolutions in the last 12 months. Their average twelve-month price target is $52.75, suggesting that the stock has a possible downside of 3.25%. The high price target for EBS is $60.00 and the low price target for EBS is $43.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.75 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $52.75 | $52.75 | $50.3333 | $45.00 |
| Price Target Upside: | 3.25% downside | 6.27% upside | 0.96% downside | 11.25% upside |
Emergent BioSolutions (NYSE:EBS) Consensus Price Target History
Emergent BioSolutions (NYSE:EBS) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Emergent BioSolutions (NYSE:EBS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Emergent BioSolutions (NYSE EBS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 82.29%
Emergent BioSolutions (NYSE EBS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Ronald Richard | Director | Sell | 7,893 | $55.00 | $434,115.00 | 31,303 |  |
| 3/12/2018 | Adam Havey | EVP | Sell | 5,842 | $52.82 | $308,574.44 | 35,756 | |
| 3/1/2018 | Adam Havey | EVP | Sell | 1,898 | $49.50 | $93,951.00 | | |
| 1/22/2018 | Jerome M Hauer | Director | Sell | 5,152 | $50.91 | $262,288.32 | 23,797 | |
| 1/2/2018 | Daniel Abdun-Nabi | CEO | Sell | 21,906 | $47.91 | $1,049,516.46 | 226,040 | |
| 12/13/2017 | Daniel Abdun-Nabi | CEO | Sell | 20,000 | $45.99 | $919,800.00 | 224,134 | |
| 12/12/2017 | Ronald Richard | Director | Sell | 23,681 | $45.02 | $1,066,118.62 | 47,091 | |
| 12/7/2017 | Zsolt Harsanyi | Director | Sell | 7,000 | $42.47 | $297,290.00 | 37,077 | |
| 11/29/2017 | Fuad El-Hibri | Chairman | Sell | 47,983 | $41.88 | $2,009,528.04 | 1,550,216 | |
| 11/14/2017 | Fuad El-Hibri | Chairman | Sell | 40,000 | $40.37 | $1,614,800.00 | | |
| 11/7/2017 | George A Joulwan | Director | Sell | 14,251 | $41.24 | $587,711.24 | 34,323 | |
| 11/3/2017 | Daniel Abdun-Nabi | CEO | Sell | 31,508 | $42.77 | $1,347,597.16 | 215,642 | |
| 9/29/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $40.50 | $1,012,500.00 | 1,555,216 | |
| 9/28/2017 | Ronald Richard | Director | Sell | 22,415 | $40.00 | $896,600.00 | 24,676 | |
| 9/27/2017 | Adam Havey | EVP | Sell | 7,885 | $39.50 | $311,457.50 | 33,931 | |
| 9/27/2017 | Daniel Abdun-Nabi | CEO | Sell | 15,000 | $39.92 | $598,800.00 | 219,134 | |
| 9/27/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $39.50 | $987,500.00 | 1,555,216 | |
| 9/27/2017 | Ronald Richard | Director | Sell | 1,266 | $40.00 | $50,640.00 | 24,676 | |
| 9/14/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $38.50 | $962,500.00 | 1,603,763 | |
| 9/8/2017 | Adam Havey | EVP | Sell | 7,885 | $37.06 | $292,218.10 | 33,931 | |
| 9/7/2017 | Fuad El-Hibri | Chairman | Sell | 16,439 | $37.50 | $616,462.50 | 1,605,216 | |
| 9/5/2017 | Fuad El-Hibri | Chairman | Sell | 3,100 | $37.50 | $116,250.00 | 1,621,655 | |
| 8/31/2017 | Daniel Abdun-Nabi | CEO | Sell | 15,000 | $37.21 | $558,150.00 | 219,134 | |
| 8/31/2017 | Fuad El-Hibri | Chairman | Sell | 5,461 | $37.50 | $204,787.50 | 1,624,755 | |
| 8/15/2017 | Jerome M Hauer | Director | Sell | 10,776 | $35.83 | $386,104.08 | 29,421 | |
| 7/27/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $36.50 | $912,500.00 | 1,630,216 | |
| 7/20/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $35.50 | $887,500.00 | 1,655,216 | |
| 4/3/2017 | Adam Havey | EVP | Sell | 11,419 | $28.62 | $326,811.78 | 26,046 | |
| 3/8/2017 | Jerome M Hauer | Director | Sell | 2,576 | $31.27 | $80,551.52 | 17,404 | |
| 1/17/2017 | Adam Havey | EVP | Sell | 8,438 | $29.75 | $251,030.50 | 41,424 | |
| 1/17/2017 | Sue Bailey | Director | Sell | 19,424 | $29.78 | $578,446.72 | 34,637 | |
| 1/10/2017 | Daniel Abdun-Nabi | Insider | Sell | 28,240 | $31.28 | $883,347.20 | 172,945 | |
| 12/13/2016 | Ronald Richard | Director | Sell | 5,900 | $34.09 | $201,131.00 | 19,870 | |
| 6/6/2016 | George A Joulwan | Director | Sell | 4,700 | $44.12 | $207,364.00 | 20,785 | |
| 6/1/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,699 | $43.74 | $380,494.26 | 170,966 | |
| 5/27/2016 | Fuad El-Hibri | Major Shareholder | Sell | 9,835 | $43.50 | $427,822.50 | 1,649,073 | |
| 5/26/2016 | Fuad El-Hibri | Major Shareholder | Sell | 39,759 | $43.13 | $1,714,805.67 | 1,698,667 | |
| 5/25/2016 | Fuad El-Hibri | Major Shareholder | Sell | 85,000 | $42.52 | $3,614,200.00 | 1,719,073 | |
| 5/25/2016 | Zsolt Harsanyi | Director | Sell | 27,867 | $42.33 | $1,179,610.11 | 41,685 | |
| 5/24/2016 | Fuad El-Hibri | Chairman | Sell | 20,000 | $42.26 | $845,200.00 | 1,719,073 | |
| 5/23/2016 | Fuad El-Hibri | Chairman | Sell | 45,000 | $42.62 | $1,917,900.00 | 1,719,073 | |
| 5/20/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,701 | $42.00 | $365,442.00 | 179,665 | |
| 5/19/2016 | Jerome M Hauer | Director | Sell | 3,134 | $41.22 | $129,183.48 | 20,085 | |
| 5/13/2016 | Louis W Sullivan | Director | Sell | 47,631 | $39.21 | $1,867,611.51 | 28,800 | |
| 5/12/2016 | Fuad El-Hibri | Major Shareholder | Sell | 25,000 | $38.71 | $967,750.00 | 1,699,073 | |
| 5/12/2016 | Jerome M Hauer | Director | Sell | 4,700 | $38.50 | $180,950.00 | 18,800 | |
| 5/11/2016 | Louis W Sullivan | Director | Sell | 9,969 | $39.25 | $391,283.25 | 38,469 | |
| 4/22/2016 | Fuad El-Hibri | Major Shareholder | Sell | 4,209 | $40.50 | $170,464.50 | 1,724,073 | |
| 4/18/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,702 | $40.17 | $349,559.34 | 194,319 | |
| 4/18/2016 | Fuad El-Hibri | Major Shareholder | Sell | 20,791 | $40.50 | $842,035.50 | 1,728,282 | |
| 4/6/2016 | Fuad El-Hibri | Major Shareholder | Sell | 50,000 | $39.00 | $1,950,000.00 | 1,774,073 | |
| 4/6/2016 | Robert Kramer | EVP | Sell | 21,786 | $38.90 | $847,475.40 | 77,551 | |
| 4/4/2016 | Robert Kramer | EVP | Sell | 21,788 | $36.90 | $803,977.20 | 80,597 | |
| 4/1/2016 | Robert Kramer | EVP | Sell | 43,572 | $35.56 | $1,549,420.32 | 91,607 | |
| 3/14/2016 | Adam Havey | EVP | Sell | 4,359 | $33.96 | $148,031.64 | 39,163 | |
| 3/14/2016 | Jerome M Hauer | Director | Sell | 2,350 | $33.88 | $79,618.00 | 14,100 | |
| 3/11/2016 | Adam Havey | EVP | Sell | 11,112 | $33.84 | $376,030.08 | 54,254 | |
| 3/11/2016 | Louis W Sullivan | Director | Sell | 14,879 | $34.03 | $506,332.37 | 43,379 | |
| 3/7/2016 | Marvin L White | Director | Sell | 33,134 | $35.42 | $1,173,606.28 | 41,100 | |
| 1/4/2016 | Sue Bailey | Director | Sell | 11,520 | $38.79 | $446,860.80 | 28,500 | |
| 12/30/2015 | Ronald Richard | Director | Sell | 21,600 | $40.00 | $864,000.00 | 13,733 | |
| 12/24/2015 | Daniel Abdun-Nabi | CEO | Sell | 63,209 | $39.06 | $2,468,943.54 | 185,368 | |
| 11/19/2015 | Fuad El-Hibri | major shareholder | Sell | 17,871 | $37.50 | $670,162.50 | 1,852,284 | |
| 11/13/2015 | Fuad El-Hibri | major shareholder | Sell | 13,013 | $36.50 | $474,974.50 | 1,842,255 | |
| 11/12/2015 | Barry Labinger | EVP | Sell | 36,126 | $35.64 | $1,287,530.64 | 28,558 | |
| 11/9/2015 | Fuad El-Hibri | major shareholder | Sell | 13,225 | $35.50 | $469,487.50 | 1,835,268 | |
| 11/6/2015 | Fuad El-Hibri | major shareholder | Sell | 13,450 | $34.50 | $464,025.00 | 1,828,493 | |
| 11/3/2015 | Fuad El-Hibri | major shareholder | Sell | 13,689 | $33.50 | $458,581.50 | 1,821,943 | |
| 9/11/2015 | Sue Bailey | Director | Sell | 6,080 | $32.37 | $196,809.60 | 28,500 | |
| 8/13/2015 | George A Joulwan | Director | Sell | 7,200 | $34.72 | $249,984.00 | | |
| 7/20/2015 | Fuad El-Hibri | Chairman | Sell | 234 | $34.50 | $8,073.00 | | |
| 7/13/2015 | Ronald Richard | Director | Sell | 4,922 | $34.00 | $167,348.00 | | |
| 6/29/2015 | Ronald Richard | Director | Sell | 4,923 | $32.76 | $161,277.48 | | |
| 6/22/2015 | Fuad El-Hibri | Major Shareholder | Sell | 74,564 | $32.60 | $2,430,786.40 | | |
| 6/16/2015 | Louis W Sullivan | Director | Sell | 13,457 | $31.33 | $421,607.81 | | |
| 6/15/2015 | Adam Havey | EVP | Sell | 36,298 | $31.55 | $1,145,201.90 | | |
| 6/15/2015 | Fuad El-Hibri | Major Shareholder | Sell | 45,436 | $32.18 | $1,462,130.48 | | |
| 1/20/2015 | Fuad El-Hibri | Major Shareholder | Sell | 15,325 | $27.67 | $424,042.75 | | |
| 12/26/2014 | Ronald Richard | Director | Sell | 5,000 | $28.00 | $140,000.00 | | |
| 12/17/2014 | Ronald Richard | Director | Sell | 5,000 | $27.00 | $135,000.00 | | |
| 12/11/2014 | Fuad El-Hibri | Major Shareholder | Sell | 119,341 | $26.00 | $3,102,866.00 | | |
| 11/28/2014 | Fuad El-Hibri | Major Shareholder | Sell | 34,577 | $25.00 | $864,425.00 | | |
| 11/25/2014 | Fuad El-Hibri | Major Shareholder | Sell | 9,014 | $25.00 | $225,350.00 | | |
| 11/25/2014 | Zsolt Harsanyi | Director | Sell | 8,000 | $24.82 | $198,560.00 | | |
| 11/12/2014 | Fuad El-Hibri | Major Shareholder | Sell | 2,311 | $25.00 | $57,775.00 | | |
| 11/7/2014 | Robert Kramer | CFO | Sell | 2,625 | $24.00 | $63,000.00 | | |
| 4/16/2014 | Robert Kramer | CFO | Sell | 50,189 | $24.34 | $1,221,600.26 | 62,183 | |
| 3/12/2014 | Adam Havey | EVP | Sell | 11,562 | $27.50 | $317,955.00 | 36,145 | |
| 3/11/2014 | Adam Havey | EVP | Sell | 17,655 | $26.96 | $475,978.80 | 36,920 | |
(Data available from 1/1/2013 forward)
Emergent BioSolutions (NYSE EBS) News Headlines
| Source: |
|
Emergent BioSolutions (NYSE:EBS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Emergent BioSolutions (NYSE:EBS) Income Statement, Balance Sheet and Cash Flow Statement
Emergent BioSolutions (NYSE EBS) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
